Medical devices, healthcare technology and the business of care
PMA approval · P240026

OncoMate MSI Dx Analysis System

Promega Corporation · Decision date Nov 5, 2025

FDA DECISIONP240026

What did the FDA approve?

FDA records P240026 as an original PMA application. The recorded decision is approval, dated Nov 5, 2025.

FDA approval order statement

Approval for the OncoMate MSI Dx Analysis System. The OncoMate MSI Dx Analysis System is a qualitative multiplex polymerase chain reaction (PCR) test intended to detect the deletion of mononucleotides in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) for the identification of microsatellite instability (MSI) using DNA obtained from formalin-fixed, paraffin-embedded (FFPE) endometrial carcinoma tissue specimens, and DNA isolated from matched normal FFPE specimen or whole blood. The OncoMate MSI Dx Analysis System is for use with the Applied Biosystems 3500 Dx Genetic Analyzer and OncoMate MSI Dx Analysis Software.The OncoMate MSI Dx Analysis System is indicated for use as a companion diagnostic test to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA (pembrolizumab) in combination with LENVIMA (lenvatinib) in accordance with the approved therapeutic product labeling.
Regulatory pathway
Original PMA
Clinical specialty
Medical Genetics
Decision date
Nov 5, 2025

FDA source record

Regulatory record facts

Identifier
P240026
Regulatory pathway
Premarket approval application
Product code
SFL
Decision code
APPR
Decision date
Nov 5, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Nucleic Acid Based Assay, Microsatellite Instability.

Product code
SFL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240026 received

    Application receipt date recorded by FDA.

  2. P240026 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P240026. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code SFL

Product / regulatory recordCompanyPathwayDecision dateSource
Promega CorporationPMA approvalSep 15, 2026FDA
Biocartis Us, Inc.PMA approvalAug 15, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Promega Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2800 Woods Hollow Rd., Madison, WI, 53711

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records